We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Alaunos (TCRT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Alaunos is a member of our Medical group, which includes 1178 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Alaunos is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for TCRT's full-year earnings has moved 20.8% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, TCRT has gained about 10.9% so far this year. Meanwhile, the Medical sector has returned an average of -16.7% on a year-to-date basis. This shows that Alaunos is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Autolus Therapeutics PLC Sponsored ADR (AUTL - Free Report) . The stock is up 4.2% year-to-date.
The consensus estimate for Autolus Therapeutics PLC Sponsored ADR's current year EPS has increased 19.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Alaunos is a member of the Medical - Drugs industry, which includes 219 individual companies and currently sits at #89 in the Zacks Industry Rank. Stocks in this group have lost about 24.2% so far this year, so TCRT is performing better this group in terms of year-to-date returns.
On the other hand, Autolus Therapeutics PLC Sponsored ADR belongs to the Medical - Biomedical and Genetics industry. This 558-stock industry is currently ranked #84. The industry has moved -17.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alaunos and Autolus Therapeutics PLC Sponsored ADR as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Alaunos (TCRT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Alaunos is a member of our Medical group, which includes 1178 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Alaunos is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for TCRT's full-year earnings has moved 20.8% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, TCRT has gained about 10.9% so far this year. Meanwhile, the Medical sector has returned an average of -16.7% on a year-to-date basis. This shows that Alaunos is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Autolus Therapeutics PLC Sponsored ADR (AUTL - Free Report) . The stock is up 4.2% year-to-date.
The consensus estimate for Autolus Therapeutics PLC Sponsored ADR's current year EPS has increased 19.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Alaunos is a member of the Medical - Drugs industry, which includes 219 individual companies and currently sits at #89 in the Zacks Industry Rank. Stocks in this group have lost about 24.2% so far this year, so TCRT is performing better this group in terms of year-to-date returns.
On the other hand, Autolus Therapeutics PLC Sponsored ADR belongs to the Medical - Biomedical and Genetics industry. This 558-stock industry is currently ranked #84. The industry has moved -17.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alaunos and Autolus Therapeutics PLC Sponsored ADR as they could maintain their solid performance.